Legal News

IP and COVID—part of the solution not part of the problem

Published on: 04 March 2021
Published by: LexisPSL
  • IP and COVID—part of the solution not part of the problem
  • First of all, it doesn’t fix the problem
  • So what can be done to continue to increase capacity and achieve what we all want—more doses to more people, more quickly?

Article summary

Life Sciences analysis: Witnessing millions of Europeans getting their vaccines just 12 months on from the first discovery of coronavirus (COVID-19), is an incredible collaborative, scientific, manufacturing and logistical achievement involving the global research community working in lockstep with the research-based pharmaceutical industry, EU institutions, governments, regulators and health-systems. Nathalie Moll, director general at European Federation of Pharmaceutical Industries and Associations, discusses the R&D and manufacturing challenges posed by the pandemic. or take a trial to read the full analysis.

Popular documents